Article

#3: Anti-VEGF Therapy for Retinal Diseases

Early animal studies showed that the injection of VEGF into the eye stimulated the growth and permeability of new vessels on the retina and also induced neovascular glaucoma.

In 1994, a series of articles was published suggesting that vascular endothelial growth factor (VEGF) played a role in ocular neovascularization. Early animal studies showed that the injection of VEGF into the eye stimulated the growth and permeability of new vessels on the retina and also induced neovascular glaucoma.

A decade later, the first anti-VEGF molecule, bevacizumab, was approved in both the United States and Europe for the treatment of colon cancer in combination with chemotherapy. Because of the suspected role of VEGF in the development and progression of neovascular (wet) age-related macular degeneration (AMD), bevacizumab quickly began being used off-label by ophthalmologists.

In December 2004, the first anti-VEGF agent indicated for use in ophthalmology, pegaptanib, was approved by the US Food and Drug Administration. Its approval in Europe followed a year later. Pegaptanib was commonly used to treat wet AMD until the approval of ranibizumab in 2011 drove the market in a new direction.

The approval of ranibizumab, a monoclonal antibody that is a modified variant of bevacizumab, sparked a wave of comparative trials between these similar agents. Both the CATT and IVAN trials showed that ranibizumab and bevacizumab had equivalent effects on visual acuity in patients with wet AMD when administered according to the same schedule. Side effects, however, were more common in patients treated with bevacizumab.

Follow-up series of patient undergoing anti-VEGF therapy acquired with AutoRescan function of SPECTRALIS(R) OCT. Blood vessel alignment across all visits demonstrates precise rescan placement.

The newest anti-VEGF agent, aflibercept, was also introduced for the treatment of wet AMD in 2011 in the United States and a year later in Europe. Developed to improve the pharmacokinetics of VEGF binding, aflibercept typically requires less frequent dosing than other anti-VEGF antibodies.

In addition to their use in wet AMD, anti-VEGF agents are commonly used to treat diabetic retinopathy and retinal vein occlusions. Anti-VEGF agents have unquestionably revolutionized the treatment of retinal disease, demonstrating visual and anatomic outcomes that far outpace the performance of previously available treatments such as laser photocoagulation.

In preparation for and to assess the effectiveness of anti-VEGF agents in patients with retinal disease, ophthalmologists use a variety of diagnostic and assessment tools, including fluorescein angiography and optical coherence tomography.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
At the Association for Research in Vision and Ophthalmology (ARVO) meeting, Katherine Talcott, MD, a retina specialist at Cleveland Clinic, shared her findings on EYP-1901 (EyePoint Pharmaceuticals) in the phase 2 DAVIO study.
Dr. Jogin Desai, founder of Eyestem Research, discusses his research at the Association for Research in Vision and Ophthalmology.
(Image credit: Ophthalmology Times) ASCRS 2025: Michael Rivers, MD, shares his takeaways as a panelist at the inaugural SightLine event
(Image credit: Ophthalmology Times) ASCRS 2025: Karl Stonecipher, MD, on LASIK outcomes using an aspheric excimer laser for high myopia
John Tan talks about an emergency triage framework for retinal artery occlusion at the 2025 Association for Research in Vision and Ophthalmology (ARVO) meeting.
Dr Robert Maloney at the 2025 Controversies in Modern Eye Care meeting
Wendy Lee, MD, MS, at Controversies in Modern Eye Care 2025.
© 2025 MJH Life Sciences

All rights reserved.